Shrewsbury, MA, United States of America

Jijie Gu

USPTO Granted Patents = 17 (Patent Applications = 19)

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 2 (Patent Applications = 16)

Average Co-Inventor Count = 5.9

ph-index = 8

Forward Citations = 259(Granted Patents)

Location History:

Shewsbury, MA (US) (2012 - 2016)
Shrewsbury, MA (US) (2014 - 2018)

Company Filing History:

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2012-2018

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9944720 - Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof (2018-04-17),

2. 9856319 - Monovalent binding proteins (2018-01-02),

3. 9840554 - Antibodies against platelet-derived growth factor (PDGF) (2017-12-12),

4. 9550986 - High-throughput antibody humanization (2017-01-24),

5. 9469689 - Therapeutic DLL4 binding proteins (2016-10-18),

6. 9469688 - Therapeutic DLL4 binding proteins (2016-10-18),

7. 9394363 - Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof (2016-07-19),

8. 9163093 - Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof (2015-10-20),

9. 9132190 - Therapeutic DLL4 binding proteins (2015-09-15),

10. 9115195 - Therapeutic DLL4 binding proteins (2015-08-25),

11. 9062108 - Dual specific binding proteins directed against IL-1 and/or IL-17 (2015-06-23),

12. 9045551 - Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof (2015-06-02),

13. 8987418 - Dual specific binding proteins directed against IL-1β and/or IL-17 (2015-03-24),

14. 8822645 - Prostaglandin E2 dual variable domain immunoglobulins and uses thereof (2014-09-02),

15. 8722855 - Dual variable domain immunoglobulins and uses thereof (2014-05-13),

Title: Innovations and Contributions of Jijie Gu

Introduction

Jijie Gu is a prominent inventor based in Shrewsbury, MA, known for his significant contributions to the field of biomedical engineering. With a total of 17 patents to his name, he has made remarkable advancements in the development of binding proteins that have potential applications in cancer treatment and other diseases.

Latest Patents

Among his latest patents is the "Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof." This patent discloses multivalent and multispecific binding proteins, along with methods for their production. These proteins are designed for use in the diagnosis, monitoring, inhibition, prevention, and treatment of cancers and other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. Another notable patent is for "Monovalent binding proteins," which details engineered monovalent binding proteins that bind to one or more ligands via a single binding domain. This innovation includes methods of making these proteins and their applications in disease prevention, diagnosis, and treatment.

Career Highlights

Jijie Gu has worked with leading companies in the pharmaceutical industry, including AbbVie Inc. and Abbott Laboratories Corporation. His work in these organizations has contributed to the advancement of therapeutic solutions that address critical health challenges.

Collaborations

Throughout his career, Jijie Gu has collaborated with esteemed colleagues, including Chung-Ming Hsieh and Yingchun Li. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Jijie Gu's contributions to the field of biomedical engineering through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for advancements in the treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.